AL58805

DRUG3 trials

Sponsors

Advenchen Laboratories Nanjing Ltd., Advenchen Pharmaceuticals, LLC.

Conditions

Advanced TumorsBreast NeoplasmsEndometrial NeoplasmsGlioblastomaOvarian NeoplasmsSoft Tissue Sarcoma (STS)

Phase 1

A Study of AL58805 in Patients With Advanced Tumors

RecruitingNCT07179081

Advenchen Laboratories Nanjing Ltd.Advanced Tumors

Start: 2020-12-20End: 2026-01-26Target: 40Updated: 2025-09-17

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers

Not yet recruitingNCT07811232

Advenchen Pharmaceuticals, LLC.Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms

Start: 2026-09-01End: 2031-09-01Target: 138Updated: 2026-09-10

A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

Not yet recruitingNCT07811297

Advenchen Pharmaceuticals, LLC.Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS) +1

Start: 2026-09-01End: 2031-09-01Target: 138Updated: 2026-09-10